146 related articles for article (PubMed ID: 16781149)
1. Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
Wang Z; Wu B; Kuhen KL; Bursulaya B; Nguyen TN; Nguyen DG; He Y
Bioorg Med Chem Lett; 2006 Aug; 16(16):4174-7. PubMed ID: 16781149
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
Jiang T; Kuhen KL; Wolff K; Yin H; Bieza K; Caldwell J; Bursulaya B; Wu TY; He Y
Bioorg Med Chem Lett; 2006 Apr; 16(8):2105-8. PubMed ID: 16480865
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
Ellis D; Kuhen KL; Anaclerio B; Wu B; Wolff K; Yin H; Bursulaya B; Caldwell J; Karanewsky D; He Y
Bioorg Med Chem Lett; 2006 Aug; 16(16):4246-51. PubMed ID: 16782337
[TBL] [Abstract][Full Text] [Related]
4. 1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
Zhan P; Liu X; Cao Y; Wang Y; Pannecouque C; De Clercq E
Bioorg Med Chem Lett; 2008 Oct; 18(20):5368-71. PubMed ID: 18824350
[TBL] [Abstract][Full Text] [Related]
5. Scaffold hopping in the rational design of novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
O'Meara JA; Jakalian A; LaPlante S; Bonneau PR; Coulombe R; Faucher AM; Guse I; Landry S; Racine J; Simoneau B; Thavonekham B; Yoakim C
Bioorg Med Chem Lett; 2007 Jun; 17(12):3362-6. PubMed ID: 17451954
[TBL] [Abstract][Full Text] [Related]
6. Optimization of 5-aryloxyimidazole non-nucleoside reverse transcriptase inhibitors.
Jones LH; Allan G; Corbau R; Hay D; Middleton DS; Mowbray CE; Newman SD; Perros M; Randall A; Vuong H; Webster R; Westby M; Williams D
ChemMedChem; 2008 Nov; 3(11):1756-62. PubMed ID: 18855969
[TBL] [Abstract][Full Text] [Related]
7. The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutations.
Tucker TJ; Saggar S; Sisko JT; Tynebor RM; Williams TM; Felock PJ; Flynn JA; Lai MT; Liang Y; McGaughey G; Liu M; Miller M; Moyer G; Munshi V; Perlow-Poehnelt R; Prasad S; Sanchez R; Torrent M; Vacca JP; Wan BL; Yan Y
Bioorg Med Chem Lett; 2008 May; 18(9):2959-66. PubMed ID: 18396399
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design, parallel synthesis, structure-activity relationship, and molecular modeling studies of thiocarbamates, new potent non-nucleoside HIV-1 reverse transcriptase inhibitor isosteres of phenethylthiazolylthiourea derivatives.
Ranise A; Spallarossa A; Cesarini S; Bondavalli F; Schenone S; Bruno O; Menozzi G; Fossa P; Mosti L; La Colla M; Sanna G; Murreddu M; Collu G; Busonera B; Marongiu ME; Pani A; La Colla P; Loddo R
J Med Chem; 2005 Jun; 48(11):3858-73. PubMed ID: 15916438
[TBL] [Abstract][Full Text] [Related]
9. Diphenyl ether non-nucleoside reverse transcriptase inhibitors with excellent potency against resistant mutant viruses and promising pharmacokinetic properties.
Sweeney ZK; Kennedy-Smith JJ; Wu J; Arora N; Billedeau JR; Davidson JP; Fretland J; Hang JQ; Heilek GM; Harris SF; Hirschfeld D; Inbar P; Javanbakht H; Jernelius JA; Jin Q; Li Y; Liang W; Roetz R; Sarma K; Smith M; Stefanidis D; Su G; Suh JM; Villaseñor AG; Welch M; Zhang FJ; Klumpp K
ChemMedChem; 2009 Jan; 4(1):88-99. PubMed ID: 19006142
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2.
Jiang T; Kuhen KL; Wolff K; Yin H; Bieza K; Caldwell J; Bursulaya B; Tuntland T; Zhang K; Karanewsky D; He Y
Bioorg Med Chem Lett; 2006 Apr; 16(8):2109-12. PubMed ID: 16464578
[TBL] [Abstract][Full Text] [Related]
11. Discovery of triazolinone non-nucleoside inhibitors of HIV reverse transcriptase.
Sweeney ZK; Acharya S; Briggs A; Dunn JP; Elworthy TR; Fretland J; Giannetti AM; Heilek G; Li Y; Kaiser AC; Martin M; Saito YD; Smith M; Suh JM; Swallow S; Wu J; Hang JQ; Zhou AS; Klumpp K
Bioorg Med Chem Lett; 2008 Aug; 18(15):4348-51. PubMed ID: 18625554
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, SAR, and molecular modeling studies of acylthiocarbamates: a novel series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors structurally related to phenethylthiazolylthiourea derivatives.
Ranise A; Spallarossa A; Schenone S; Bruno O; Bondavalli F; Vargiu L; Marceddu T; Mura M; La Colla P; Pani A
J Med Chem; 2003 Feb; 46(5):768-81. PubMed ID: 12593657
[TBL] [Abstract][Full Text] [Related]
13. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
[TBL] [Abstract][Full Text] [Related]
14. Parallel one-pot synthesis and structure-activity relationship study of symmetric formimidoester disulfides as a novel class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
Cesarini S; Spallarossa A; Ranise A; Schenone S; Bruno O; La Colla P; Casula L; Collu G; Sanna G; Loddo R
Bioorg Med Chem; 2008 Jun; 16(12):6353-63. PubMed ID: 18502646
[TBL] [Abstract][Full Text] [Related]
15. [d4U]-butyne-[HI-236] as a non-cleavable, bifunctional NRTI/NNRTI HIV-1 reverse-transcriptase inhibitor.
Hunter R; Muhanji CI; Hale I; Bailey CM; Basavapathruni A; Anderson KS
Bioorg Med Chem Lett; 2007 May; 17(9):2614-7. PubMed ID: 17317163
[TBL] [Abstract][Full Text] [Related]
16. Activity and molecular modeling of a new small molecule active against NNRTI-resistant HIV-1 mutants.
Carta A; Pricl S; Piras S; Fermeglia M; La Colla P; Loddo R
Eur J Med Chem; 2009 Dec; 44(12):5117-22. PubMed ID: 19775780
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity.
Heeres J; de Jonge MR; Koymans LM; Daeyaert FF; Vinkers M; Van Aken KJ; Arnold E; Das K; Kilonda A; Hoornaert GJ; Compernolle F; Cegla M; Azzam RA; Andries K; de Béthune MP; Azijn H; Pauwels R; Lewi PJ; Janssen PA
J Med Chem; 2005 Mar; 48(6):1910-8. PubMed ID: 15771435
[TBL] [Abstract][Full Text] [Related]
18. Novel N1-substituted 1,3-dihydro-2H-benzimidazol-2-ones as potent non-nucleoside reverse transcriptase inhibitors.
Monforte AM; Rao A; Logoteta P; Ferro S; De Luca L; Barreca ML; Iraci N; Maga G; De Clercq E; Pannecouque C; Chimirri A
Bioorg Med Chem; 2008 Aug; 16(15):7429-35. PubMed ID: 18585918
[TBL] [Abstract][Full Text] [Related]
19. Novel 8-substituted dipyridodiazepinone inhibitors with a broad-spectrum of activity against HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitors.
O'Meara JA; Yoakim C; Bonneau PR; Bös M; Cordingley MG; Déziel R; Doyon L; Duan J; Garneau M; Guse I; Landry S; Malenfant E; Naud J; Ogilvie WW; Thavonekham B; Simoneau B
J Med Chem; 2005 Aug; 48(17):5580-8. PubMed ID: 16107158
[TBL] [Abstract][Full Text] [Related]
20. Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses.
Côté B; Burch JD; Asante-Appiah E; Bayly C; Bédard L; Blouin M; Campeau LC; Cauchon E; Chan M; Chefson A; Coulombe N; Cromlish W; Debnath S; Deschênes D; Dupont-Gaudet K; Falgueyret JP; Forget R; Gagné S; Gauvreau D; Girardin M; Guiral S; Langlois E; Li CS; Nguyen N; Papp R; Plamondon S; Roy A; Roy S; Seliniotakis R; St-Onge M; Ouellet S; Tawa P; Truchon JF; Vacca J; Wrona M; Yan Y; Ducharme Y
Bioorg Med Chem Lett; 2014 Feb; 24(3):917-22. PubMed ID: 24412110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
